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Purpose. Hypercholesterolemia and tight junctions play important roles in atherosclerosis. But the relationship between these
two factors is unclear. In the present study, we investigated whether hypercholesterolemic serum could change the permeability
of endothelial cells through altering expression and/or distribution of tight junction protein zonula occludens-1 (ZO-1).
Phosphatidylinositol 3-kinase (PI3K) signaling pathway was also examined. Materials and Methods. Cultured endothelial cells
were treated with diﬀerent concentration levels of hypercholesterolemic serum. The expression and distribution of ZO-1, the
permeability of cultured cells and the involvement of PI3K signaling pathway were measured by various methods. Results.I nt h e
present study, we found that hypercholesterolemic serum could not change the expression of ZO-1 either in mRNA or protein
level. However, hypercholesterolemic serum could change the distribution of ZO-1 in cultured endothelial cells, and increase
the permeability with a dose-dependent manner. When PI3K speciﬁc inhibitor wortmannin was used, the eﬀects induced by
hypercholesterolemic serum could be partly reversed. The role of PI3K signaling pathway was further conﬁrmed by PI3K activity
assay. Conclusions. Our results suggested that although hypercholesterolemic serum could not change the expression of ZO-1, it
could change the distribution and increase the permeability in endothelial cells through PI3K signaling pathway.
Copyright © 2009 Chang Bian et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Elevated permeability of endothelium is crucial in ather-
osclerosis because it allows circulating lipoproteins and
inﬂammatory cells to inﬁltrate into intima. The barrier
function is maintained partially by tight junctions between
adjacent endothelial cells [1]. Zonula occludens-1 (ZO-1)
plays an important role in binding occludin to cytoar-
chitecture [2] and regulating cellular permeability [3].
Hypercholesterolemia is known as a major risk factor
for atherosclerosis. However, whether hypercholesterolemic
serum can lead to atherosclerosis through inﬂuencing cell
j u n c t i o n si ss t i l lu n c l e a r .S oi nt h i ss t u d y ,w ei n v e s t i g a t e dt h e
eﬀect of hypercholesterolemic serum on ZO-1 organization
and endothelial permeability. Due to the involvement in
theregulationofZO-1,phosphatidylinositol3-kinase(PI3K)
signaling pathway was also examined.
2.MaterialandMethods
2.1. Hypercholesterolemic Serum Preparation. Rabbits in
group A were fed with a 1% high cholesterol diet and rabbits
in group B were fed with normal diet for 4 weeks. Five
rabbits’ peripheral blood in each group was collected via
ear vein. Serum was isolated by centrifugation, respectively,
and mixed well for further studies. Total serum choles-
terol was measured with an enzymatic timed end-point
method automatically. All procedures were in accordance
with the guiding principles of Zhejiang University School of
Medicine, the principles of the American Heart Association
on Research Animal Use, and the Guide for the Care and
Use of Laboratory Animals published by the US National
Institute of Health (NIH Publication no. 85-23, revised
1996).2 Journal of Biomedicine and Biotechnology
2.2. HUVECs Culture and Treatment. Human umbilical
vascular endothelial cells (HUVECs) were prepared as in
the previous report [4]. Cells were grown in RPMI-1640
medium (Genom Biomed, China) with 20% fetal bovine
serum (Sijiqing Biological, China) at 37
◦C in a humidiﬁed
atmosphere of 5% CO2. Cells were replaced with serum-
free medium when they achieved 90% conﬂuence and
were treated with serum-free RPMI-1640 medium (control),
diﬀerent concentration of hypercholesterolaemic serum or
combined with PI3K inhibitor wortmannin (Sigma, USA)
for 24 hours.
2.3. Western Blot Analysis. Aliquots of cell lysates were sepa-
rated by 11% SDS-polyacrylamide gel, and then transferred
to nitrocellulose membrane ﬁlters. The ﬁlters were blocked
with TBS-T buﬀer, containing 20% skim milk, incubated
with a mouse monoclonal antibody to human ZO-1 (1:400)
(Zymed, USA) for 2 hours at room temperature, and
followed by the addition of goat antimouse IgG(H+L)/HRP
secondary antibody (1:10000) (Pierce, USA), and ECL
(Pierce, USA) visualization of the bands. All tests assayed
by western blot were repeated three times. Expression was
quantitated by software Quantity-one (Bio-Rad, USA). β-
actin (Santa Crutz, USA) was used as input control.
2.4. RT-PCR. RNA was puriﬁed using Minikit (Qiagen,
German) according to the manufacturer’s procedure and
dissolved in 20μL DEPC-treated water. Total RNA of
HUVECs was converted into cDNA with oligo dT15 by M-
MuLV reverse transcriptase (Fermentas, Lithuania). RT-PCR
was performed with primers as follows: forward primer:
5 -AAAAGTGAACCACGAGATGCT-3 , reverse primer: 5 -
AAAGGTAAGGGACTGGAGATGA-3 . The reaction condi-
tions for ZO-1 were 1×(94◦C, 4min), 30×(94◦C, 30s;
51.5◦C, 30s; 72◦C, 45s), and 1×(72◦C, 10min). PCR
products were run in 1% agarose gel. And the images were
analyzed by Kodak Digital Science ID software. β-Actin was
used as the input control.
2.5. Immunoﬂuorescent Staining. Endothelial monolayer was
ﬁxedwithmethanolfor15minutesat−20
◦C.Themonolayer
was blocked with 1% bovine serum albumin (BSA) (Sigma,
USA) in TBS-T (20mM Tris, pH 7.2, and 150mM NaCl),
incubated with primary antibody, a mouse monoclonal
antibody to human ZO-1, in PBS with 1% BSA overnight
at 4◦C, and followed by incubation with FITC-conjugated
secondary antibodies (Pierce, USA) at 37
◦Cf o r1h o u r .
Endothelial monolayer was rinsed three times with PBS
before being sealed with 50% glycerol-PBS. Sections were
examined by the OLYMPUS BX60 ﬂuorescence microscope
at 450nm.
2.6. Permeability Assay. Endothelial cells were seeded
(100,000 cells/insert) on gelatin-coated (1%) polystyrene
ﬁlters (Costar Transwell, 0.4-μm pore size) (Corning, USA),
grown to conﬂuence on transwell inserts, and replaced
with serum-free RPMI-1640 medium (control), diﬀerent
concentration of hypercholesterolaemic serum or combined
with PI3K inhibitor wortmannin for 3 hours. 10mg/mL BSA
inserum-freemediumwasaddedtotheuppercompartment.
Fluid in the lower compartment was the same serum-free
medium without BSA. The transfer rate of BSA across the
monolayer was assessed by measuring the rise of BSA in the
lower well after 30 minutes. BSA was quantiﬁed with an Elisa
kit.
2.7. Elisa Assay. Elisa assay (Alpha Diagnostic, USA) was
performed as instruction. Brieﬂy, 100μL diluted samples
were added to each well. Plates were incubated at room
temperature for 60 minutes. Plates were washed ﬁve times
with washing buﬀer and incubated with 100μLo fH R P -
labeled antibovine albumin conjugate at room temperature
for 30 minutes. Plates were then washed ﬁve times with
washing buﬀer and incubated with 100μLo fT M Bs u b s t r a t e
solution at room temperature for 15 minutes. The ELISA
was stopped with 100μL/well stop solution and read at OD
450nm.
2.8. PI3K Activity Assay. T h eP I 3 Ka c t i v i t ya s s a yw a sp e r -
formed as described previously [5]. After treatment of
high-cholesterol serum, cells were harvested and the PI3K
complexes were pulled down by PI3K antibody. To measure
PI3K activity, a TLC-based assay was employed by using
phosphatidylinositol 4-5-biphosphate (PIP2) as a substrate.
The PI (3,4,5) P3 was quantiﬁed by using Molecular
Dynamics PhosphorImager. And the phosphorylated prod-
ucts were quantiﬁed by excising the spot and scintillation
counting (count per minute).
2.9. Statistical Analysis. All statistical calculations were per-
formed with the SPSS 11.5 statistical software package (SPSS
Inc). The results were representative of three experiments
with diﬀerent cell preparation in each condition. The data
were expressed as mean ± standard deviation. Results were
analyzed by One-Way ANOVA. P ≤ .05 were considered to
be statistically signiﬁcant.
3. Results
3.1. Serum Cholesterol Level after a High-Cholesterol Diet.
After 4 weeks of 1% high cholesterol diet, there was a
signiﬁcant increase in serum cholesterol in tested animals
compared with controls (33.9±9.4v e r s u s1 .3±0.6mMol/L,
P<. 01).
3.2. Expression of ZO-1 mRNA and Protein in Hypercho-
lesterolemic-Treated HUVECs. The expression of ZO-1 in
endothelial cells after hypercholesterolemic serum (choles-
terol concentrations: 0.04, 0.08, 0.16, and 0.32mMol/L)
exposure was shown in Figure 1(a). The results of RT-PCR
revealed that hypercholesterolemic serum could not change
the expression of ZO-1 mRNA signiﬁcantly. Figure 1(b)
indicated the eﬀects of hypercholesterolemic serum on
ZO-1 protein expression as measured by western blotting.
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Figure 1: Hypercholesterolemic serum could not change ZO-
1 expression in mRNA (a) or protein (b) level. a: serum free
medium; b: normal rabbit serum; c–f: hypercholesterolemic serum
at diﬀerent cholesterol concentrations. Z/a ratio was calculated as
below: the ratio of ZO-1 to actin in control group was regarded as 1
in every test. And Z/a ratio in other groups was adjusted to control
group.
for 24 hours could not alter ZO-1 protein expression as
compared with the control group (Figure 1).
3.3. Subcellular Localization of ZO-1 Was Changed by Hyper-
cholesterolemic Serum. The permeability of human endothe-
lialcellsisgovernedinpartbytheexpressionandlocalization
of tight junctional proteins as ZO-1. Figure 2 showed the
immunoﬂuorescent staining of ZO-1 in HUVECs. ZO-1
in control group was distributed continuously around the
periphery of the cells. Compared with the control, the cells
exposed to hypercholesterolemic serum showed a loss of
junctional ZO-1 localization with subsequent staining. And
(a) (b)
(c) (d)
(e) (f)
Figure 2: Hypercholesterolemic serum could alter the distribution
of ZO-1 in endothelial cells, which seemed to be dose dependent.
PI3K speciﬁc inhibitor wortmannin could signiﬁcantly reverse
the eﬀect induced by hypercholesterolemic serum. (a) serum free
medium; (b) normal rabbit serum; (c) low concentration of hyper-
cholesterolemic serum (0.04mMol/L); (d) high concentration of
hypercholesterolemic serum (0.32mMol/L); (e) c plus 100nMol/L
wortmannin; (f) d plus 100nMol/L wortmannin.
the dose of hypercholesterolemic serum at study concentra-
tions was positively related with the redistribution of ZO-1
(Figure 2).
3.4. Monolayer Endothelial Permeability Was Increased when
Exposed to Hypercholesterolemic Serum. In previous studies,
we found that hypercholesterolemic serum could change the
distribution of ZO-1 in endothelial cells. To conﬁrm whether
hypercholesterolemic serum could change the permeability
of endothelial cells, transwell was used to observe the
permeability of endothelial cells to BSA. We found that
hypercholesterolemic serum could signiﬁcantly increase the
permeability of endothelial cells. The permeability highly
dependedontheconcentrationlevelofhypercholesterolemic
serum as shown in Figure 3.
3.5. PI3K Signaling Pathway Was Involved in the ZO-1
Regulation. To investigate the role of PI3K in the regulation
of ZO-1, we used both PI3K activity assay and PI3K speciﬁc
inhibitor wortmannin in the present study. In PI3K activity4 Journal of Biomedicine and Biotechnology
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Figure 3: Hypercholesterolemic serum could signiﬁcantly increase
thepermeabilityofendothelialcells,whichwasdetectedbyalbumin
permeability test with transwell. And the permeability of endothe-
lial cells increased with the concentration of hypercholesterolemic
serum. a: serum free medium; b: normal rabbit serum; c: low
concentration of hypercholesterolemic serum (0.04mMol/L); d:
high concentration of hypercholesterolemic serum (0.32mMol/L);
e: c plus 100nMol/L wortmannin; f: d plus 100nMol/L. ∗
represents P<. 05 compared with serum-free medium control; #
represents P<. 05 compared with previous group.
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Figure 4: In PI3K activity assay, it was found that hypercholes-
terolemic serum could signiﬁcantly enhance PI3K activity with a
dose-dependent manner, which could be reversed by wortmannin.
a:serumfreemedium;b:normalrabbitserum;c:lowconcentration
of hypercholesterolemic serum (0.04mMol/L); d: high concen-
tration of hypercholesterolemic serum (0.32mMol/L); e: c plus
100nMol/L wortmannin;f:d plus100nMol/L. ∗represents P<. 05
compared with serum-free medium control; # represents P<. 05
compared with the previous group.
assay, hypercholesterolemic serum is found to increase PI3K
activity, which could be reversed with PI3K speciﬁc inhibitor
wortmannin (Figure 4). And as shown in Figures 2 and
3, hypercholesterolemic serum induced ZO-1 redistribution
and permeability enhancement could be signiﬁcantly inhib-
ited by 100nMol/L wortmannin. So PI3K signaling pathway
wasundoubtedly involved intheZO-1regulationinduced by
hypercholesterolemic serum.
4. Discussion
Hypercholesterolemia is closely related to the function of
vascular endothelial cells [6] and can increase vascular
permeability and lead to atherosclerosis [7]. Tight junctions
contribute to cell-to-cell contacts in the paracellular cleft
and are critical for restricting paracellular diﬀusion among
endothelial cells. So it is suspected that hypercholesterolemia
could increase permeability with tight junction-related
pathways. However, the relationship between hypercholes-
terolemia and tight junctions is still unclear. In the present
study, we found that hypercholesterolemic serum could alter
the distribution of ZO-1 in endothelial cells, but could
not change the expression of ZO-1 in both mRNA and
protein levels. Due to the limitation of our study, the exact
mechanism how hypercholesterolemic serum led to the
increasing permeability was not elucidated yet. Some other
studies suggested that VEGF might be an interpretation for
its capability to rearrange endothelial junctional proteins
[8, 9]. Obviously, further studies are necessary to clarify
it.
ZO-1 acts as the scaﬀold to organize occludin at cell
junction sites [10] and links occludin to actin cytoskeleton
[11]. The expression and distribution of ZO-1 can signif-
icantly inﬂuence cell permeability and functions [3, 12].
In the present study, we found that hypercholesterolemic
serum could alter the distribution of ZO-1, while leave
the expression of ZO-1 unchanged. In the further per-
meability assay, we found that the barrier function of
endothelium was signiﬁcantly impaired after being exposed
to hypercholesterolemic serum. These results suggested that
hypercholesterolemic serum could increase the permeability
of endothelial cells through alternation of the distribution of
ZO-1. Fischer et al. believed that hyperpermeability induced
by H2O2 was caused by activation of mitogen-activated
protein kinase through redistribution of tight junction
proteins [13]. PKC signaling pathway was also found to
be involved in the regulation of ZO-1. Meanwhile, Sheth
et al. found that PI3K signaling pathway was involved in
oxidative stress-induced disruption of tight junctions [14].
Andinthepresentstudy,wefoundthathypercholesterolemic
serum-induced alternation could be signiﬁcantly attenuated
by PI3K speciﬁc inhibitor wortmannin, which was further
conﬁrmed by the PI3K activity assay. These results revealed
that PI3K signal pathway was at least partly involved
in the ZO-1 regulation induced by hypercholesterolemic
serum.
5. Conclusions
In conclusions, our study suggested that hypercholes-
terolemic serum could alter the distribution of ZO-1 and
increase the permeability in endothelial cells, at least partly
through PI3K signaling pathway.
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